Biochemical and Biophysical Research Communications
Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer
Highlights
► JMJD2B is required for cell proliferation and in vivo tumorigenesis. ► JMJD2B depletion induces apoptosis and/or cell cycle arrest. ► JMJD2B depletion activates DNA damage response and enhances p53 stabilization. ► JMJD2B is overexpressed in human primary gastric cancer.
Introduction
Gastric cancer is one of the most common malignancies and second leading cause of cancer-related death worldwide [1], [2]. Numerous studies have demonstrated the role of Helicobacter pylori infection in gastric malignant transformation. Persistent infection with H. pylori causes chronic gastritis, which initiates the pathogenesis of gastric cancer. However, the progression into invasive cancer is a multistep process with numerous alterations, with the underlying molecular mechanism poorly understood [1], [2], [3], [4]. In addition, because of lack of reliable early diagnostic markers, the prognosis of gastric cancer remains poor, with a low 5-year survival rate [2]. Therefore, better defining the pathogenesis of gastric cancer and exploring novel therapeutic targets is urgent.
Posttranslational modifications of histones regulate chromatin structure and gene expression. Histone demethylases (HDMs) remove methyl groups from the lysine residues of the histone tails, thereby regulating the transcriptional activity of target genes [5], [6]. Jumonji domain containing 2B (JMJD2B) is a newly identified member of the histone demethylase JMJD2 family that is characterized by the catalytic Jumonji C (JmjC) domain. JMJD2B specifically targets the trimethylated lysine 9 of histone H3 (H3K9) for demethylation at pericentric heterochromatin and euchromatin [7], [8], [9]. Abnormalities in the balance in methylation status of histones because of dysregulated histone methyltransferases and demethylases have been linked to cancer [10], [11]. Recent studies have indicated the role of JmjC proteins in tumorigenesis [12], [13], [14], [15]. Members of the JMJD2 family that target H3K9me3/me2 and H3K36me3/me2 are highly expressed in prostate cancer. JMJD2C/GASC1 associates with the androgen receptor and promotes proliferation of prostate cancer cells [16]. The gene encoding JMJD2C is amplified in esophageal cancer cell lines and is required for their proliferation [12], [17]. Recently, JMJD2B was found as a direct target of hypoxia-inducible factor 1 α (HIF1α) and regulated by HIF1α and estrogen receptor α (ERα) in breast cancer [15], [18] and promoted hormonally responsive breast carcinogenesis [9], [19]. However, few data exist on the expression and role of JMJD2B in other human cancers.
In the present study, we explored the potential oncogenic activities of JMJD2B and its expression profile in human gastric cancer.
Section snippets
Cell lines and culture conditions
Human gastric cancer cell lines AGS, HGC-27 and BGC-823, and cervical cancer cell line HeLa were cultured at 37 °C, 95% air, 5% CO2 in RPMI 1640 (Invitrogen) containing 10% fetal calf serum, 100 U/mL penicillin (Sigma) and 2 mmol/L l-glutamine.
Small interfering RNA (siRNA) treatment
Chemical modified Stealth™ siRNA targeting JMJD2B and control siRNA were from Invitrogen. The sequence for JMJD2B siRNA was 5′-UCU CCA UCA CCU GCC UCA AGC ACA A-3′. siRNA for p53 was from Santa Cruz Biotechnology (sc-29435). Cells were transfected with siRNA
Impaired clonogenic potentials of tumor cells treated with JMJD2B siRNA
We knocked down the expression of JMJD2B using its specific siRNA in the gastric cancer cells AGS, BGC-823 and HGC-27 and cervical HeLa cells. Efficient silencing of JMJD2B expression in all these cells was verified by RT-PCR and Western blot analysis (Fig. 1A and C). Knockdown of JMJD2B led to significantly reduced foci numbers and sizes of all cell lines as compared with the control (AGS cells: 74 ± 23 vs. 4 ± 3; HeLa cells: 235 ± 45 vs. 37 ± 10; BGC-823 cells: 122 ± 10 vs. 27 ± 9; HGC-27: 189 ± 4 vs. 120 ±
Discussion
The JMJD2 family of histone demethylases has four members, JMJD2A, B, C and D, that demethylate trimethylated histone H3 lysine 9 (H3K9) [7], [26]. JMJD2 family proteins promote transcriptional activation, thereby affecting important processes such as the hormone response, stem cell renewal, germ cell development, and cellular proliferation and differentiation [18]. The involvement of JMJD2B in tumorigenesis has been supported by recent findings of high expression of JMJD2B in ER-positive
Acknowledgments
This work was supported by the National Natural Science Foundation of China (No. 81000868, 81171536 and 30972775), Science Foundation for Outstanding Young Scientists of Shandong Province (No. BS2009SW025), the National Basic Research Program of China (973 Program, No. 2012CB911202), the Science Foundation of the Ministry of Education of China (No. 20090131120057), Shandong Provincial Natural Science Foundation (No. ZR2009CZ001 and ZR2009CM002) and the Innovation Foundation of Shandong Province
References (27)
- et al.
Carcinogenesis of Helicobacter pylori
Gastroenterology
(2007) - et al.
Dynamic regulation of histone lysine methylation by demethylases
Mol. Cell
(2007) - et al.
Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases
Cell
(2006) - et al.
The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells
Gastroenterology
(2010) - et al.
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation
Mol. Cell
(2007) - et al.
The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF
J. Biol. Chem.
(2008) - et al.
Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability
J. Biol. Chem.
(2010) - et al.
Complicated tails: histone modifications and the DNA damage response
Cell
(2005) - et al.
ATM phosphorylates histone H2AX in response to DNA double-strand breaks
J. Biol. Chem.
(2001) - et al.
DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139
J. Biol. Chem.
(1998)
Diversity within the JMJD2 histone demethylase family
Biochem. Biophys. Res. Commun.
Molecular basis of gastric cancer development and progression
Gastric Cancer
Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis
J. Cell. Physiol.
Cited by (69)
Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer
2023, Biomedicine and PharmacotherapyIdentification of the upstream regulators of KDM5B in gastric cancer
2022, Life SciencesCitation Excerpt :Altered expression of histone lysine-specific demethylases plays an important role in human gastric cancer (GC) [2–6]. It is reported that lysine-specific demethylase 1A, 2A, 4B, and 5A promote GC cell growth, invasion, and migration via small extracellular vesicles [3], programmed cell death 4 [4], p53 and p21 proteins [5], or vascular endothelial growth factor [6]. Hence, drugs targeting these demethylases may provide additional choice for GC targeting therapy [2,7–9].
Histone Chaperone ASF1A Predicts Poor Outcomes for Patients With Gastrointestinal Cancer and Drives Cancer Progression by Stimulating Transcription of β-Catenin Target Genes
2017, EBioMedicineCitation Excerpt :For instance, up-regulation of histone deacetylases while down-regulation of histone acetyltransferases is widespread in GIC (Kramer, 2009; Ozdag et al., 2006; Song et al., 2005); the histone demethylase RBP2 is frequently over-expressed in GC and promotes cancer cell proliferation and invasion (Zeng et al., 2010). In addition, altered expression and activities of JMJD2B, EZH2 and other histone modifying enzymes have been observed in GIC tumors, too (Crea et al., 2012; Kim and Roberts, 2016; Li et al., 2011; L. Zhao et al., 2014). Consistent with these alterations, there exist widespread aberrations of histone modification profiles in GIC, which has been shown to be closely associated with disease prognosis and treatment efficacy (Benard et al., 2015; Goossens-Beumer et al., 2014; Paul et al., 2015; Saldanha et al., 2014; Tamagawa et al., 2013; Wei et al., 2016).
TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase
2023, Anti-Cancer Drugs